Levodopa + Carbidopa + Entacapona Tecnigen

Levodopa/Carbidopa/Entacapone, the active ingredient in Levodopa + Carbidopa + Entacapone Tecnigen, is an antiparkinson agent presented as an oral tablet for oral use. It treats the motor symptoms of Parkinson's disease in adults.

GNH USA supplies Levodopa + Carbidopa + Entacapone Tecnigen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levodopa/Carbidopa/Entacapone is used in the management of Parkinson's disease and related motor fluctuations.

- Parkinson's disease: improves overall motor control and reduces rigidity and bradykinesia. - Motor fluctuations (wearing‑off): shortens OFF periods and extends ON time. - Advanced Parkinson's disease: enhances the effectiveness of levodopa therapy when monotherapy is insufficient.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dyskinesia: involuntary movements, especially at higher doses. - Orthostatic hypotension: dizziness upon standing. - Headache: transient cranial discomfort. - Insomnia: difficulty initiating or maintaining sleep. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or anaphylaxis. - Neuroleptic malignant syndrome: high fever, muscle rigidity, autonomic instability. - Hallucinations or psychosis: visual or auditory disturbances. - Severe depression or suicidal thoughts. - Cardiac arrhythmias: irregular heart rhythm. - Hepatic dysfunction: elevated liver enzymes or jaundice.

Before initiating therapy, clinicians should consider patient‑specific factors and monitor for adverse events. - Cardiovascular disease: monitor blood pressure and heart rate due to orthostatic effects. - Liver function: assess baseline enzymes as entacapone is hepatically metabolised. - Psychiatric history: watch for hallucinations, confusion, or mood changes. - Pregnancy and lactation: safety unknown; use only if potential benefit justifies risk. - Store at ambient temperature: keep in original container, protect from moisture and light.

Levodopa/Carbidopa/Entacapone may interact with several drug classes; careful review is required.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Antipsychotics (dopamine antagonists): may diminish antiparkinson efficacy. - Iron or calcium supplements: reduce levodopa absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Selective MAO‑B inhibitors: may increase dopaminergic activity. - Antihypertensive agents: additive blood‑pressure lowering effect. - Carbamazepine and other enzyme inducers: may lower plasma levels of entacapone. - SSRIs or SNRIs: monitor for serotonin syndrome, though risk is low.